Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Depomed’s Glumetza Q3 Launch Will Be Executed By King

This article was originally published in The Pink Sheet Daily

Executive Summary

Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.

You may also be interested in...



Depomed Takes ProQuin XR Rights Back From Esprit

Firm will leverage its Glumetza commercial structure to sell and distribute the proprietary ciprofloxacin formulation in the U.S.

Depomed Takes ProQuin XR Rights Back From Esprit

Firm will leverage its Glumetza commercial structure to sell and distribute the proprietary ciprofloxacin formulation in the U.S.

King Specialty Cardiovascular/Metabolics Force To Be In Place By September

Second quarter Altace sales up $10 mil. as Wyeth co-promotion winds down.

Related Content

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel